Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1% cholesterol, or each of the five experimental treatments (Kampo formulas 1% keishibukuryogan [KBG], 1% orengedokuto [OGT], and 1% shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1% cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2′-deoxyguanosine (P < 0.05), hepatic α-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.
Get full access to this article
View all access options for this article.
References
1.
Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Morimoto S, Yamaguchi N, Kanda T. Traditional Chinese medicine and Kampo: a review from the distant past for the future. J Int Med Res34:231–239, 2006.
2.
Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology29:149–160, 1999.
3.
Nozaki K, Hikiami H, Goto H, Nakagawa T, Shibahara N, Shimada Y. Keishibukuryogan (gui-zhi-fu-ling-wan), a kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis. Evid Based Complement Alternat Med3: 359–364, 2006.
4.
Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, Oyama K, Yashima K, Kishimoto Y, Nakai Y, Miura T, Ito H, Murawaki Y, Kawasaki H. Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2′-deoxyguanosine formation. Hepatology35:1125–1133, 2002.
5.
Sekiya N, Tanaka N, Itoh T, Shimada Y, Goto H, Terasawa K. Keishi-bukuryo-gan prevents the progression of atherosclerosis in cholesterol-fed rabbit. Phytother Res13:192–196, 1999.
6.
Sekiya N, Kainuma M, Hikiami H, Nakagawa T, Kouta K, Shibahara N, Shimada Y, Terasawa K. Oren-gedoku-to and Keishi-bukuryo-gan-ryo inhibit the progression of atherosclerosis in diet-induced hyper-cholesterolemic rabbits. Biol Pharm Bull28:294–298, 2005.
7.
Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA288:1723–1727, 2002.
8.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology43:S99–S112, 2006.
9.
Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastro-enterology114:842–845, 1998.
10.
Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol281:G1135–1139, 2001.
11.
Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther15:1667–1672, 2001.
12.
Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med355:2297–2307, 2006.
13.
Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, Terasawa K, Shimada Y. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol41:971–980, 2006.
14.
Chen MF, Hsu HC, Liau CS, Lee YT. The role of vitamin E on the anti-atherosclerotic effect of fish oil in diet-induced hypercholesterolemic rabbits. Prostaglandins Other Lipid Mediat57:99–111, 1999.
15.
Moroe H, Fujii H, Honda H, Arai K, Kanazawa M, Notoya Y, Kogo H. Characterization of endothelium-dependent relaxation and modulation by treatment with pioglitazone in the hypercholesterolemic rabbit renal artery. Eur J Pharmacol497:317–325, 2004.
16.
Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int25:779–786, 2005.
17.
Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE. Brain adipocytokine action and metabolic regulation. Diabetes55 Suppl 2: S145–154, 2006.
18.
Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol37:206–213, 2002.
19.
Kowdley KV, Pratt DS. Adiponectin—tipping the scales from NAFLD to NASH? Gastroenterology128:511–513, 2005; author reply 513.
20.
Cohen MH. Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulation. Dermatol Ther16:77–84, 2003.
21.
Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol24:5457–5464, 2006.
22.
Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun350:385–391, 2006.
23.
Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem279:11392–11401, 2004.
24.
Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol28:298–306, 1998.
25.
Yokozawa T, Chen CP, Tanaka T. Direct scavenging of nitric oxide by traditional crude drugs. Phytomedicine6:453–463, 2000.
26.
Satoh K, Nagai F, Ushiyama K, Yasuda I, Seto T, Kano I. Inhibition of Na+, K(+)-ATPase by 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, a major constituent of both moutan cortex and Paeoniae radix. Biochem Pharmacol53:611–614, 1997.
27.
Heinonen M. Antioxidant activity and antimicrobial effect of berry phenolics—a Finnish perspective. Mol Nutr Food Res51:684–691, 2007.
28.
Gao Z, Huang K, Yang X, Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta1472:643–650, 1999.
29.
Choi DS, Kim SJ, Jung MY. Inhibitory activity of berberine on DNA strand cleavage induced by hydrogen peroxide and cytochrome c. Biosci Biotechnol Biochem65:452–455, 2001.
30.
Nakagawa T, Yokozawa T, Terasawa K, Nakanishi K. Therapeutic usefulness of Keishi-bukuryo-gan for diabetic nephropathy. J Pharm Pharmacol55:219–227, 2003.
31.
Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology34:1158–1163, 2001.
32.
Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol95: 3584–3589, 2000.
33.
Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol143: 293–311, 2000.
34.
Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology40:46–54, 2004.
35.
Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology125:1796–1807, 2003.
36.
Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med8: 1288–1295, 2002.
37.
Czaja MJ. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology40:19–22, 2004.
38.
Yang G, Li L, Tang Y, Boden G. Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: possible role of the resistin and adiponectin. Biochem Biophys Res Commun339:1190–1196, 2006.
39.
Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol44:253–261, 2006.
40.
Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terauchi Y, Froguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem279:30817–30822, 2004.
41.
Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology46:424–429, 2007.
42.
Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun28:69–75, 2007.
43.
Duhalde-Vega M, Loureiro ME, Mathieu PA, Retegui LA. The peptide specificities of the autoantibodies elicited by mouse hepatitis virus A59. J Autoimmun27:203–209, 2006.
44.
Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med132:112–117, 2000.
45.
Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest114:147–152, 2004.
46.
Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem38:203–217, 2005.
47.
Savransky V, Nanayakkara A, Vivero A, Li J, Bevans S, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia predisposes to liver injury. Hepatology45:1007–1013, 2007.
48.
Shternhall-Ron K, Quintana FJ, Perl S, Meivar-Levy I, Barshack I, Cohen IR, Ferber S. Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. J Autoimmun28:134–142, 2007.
49.
Kobayashi H, Mizuno N, Teramae H, Kutsuna H, Ueoku S, Onoyama J, Yamanaka K, Fujita N, Ishii M. Diet and Japanese herbal medicine for recalcitrant atopic dermatitis: efficacy and safety. Drugs Exp Clin Res30:197–202, 2004.
